Phytosys (Visikol)
Biotech company focused on transforming tissues in 3D insights to accelerate drug discovery and improve the diagnosis of disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
$7.5m Valuation: $7.5m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Visikol is a contract research organization (CRO) specializing in advanced drug discovery solutions. The company offers a comprehensive suite of services including 3D cell culture assays, high content screening, confocal microscopy, and digital pathology. Visikol's proprietary technologies transform tissues and cells into quantitative data sets, enabling detailed analysis of biomarkers and cells. The company serves pharmaceutical and biotech clients, helping them accelerate drug discovery and development. Visikol operates in the highly specialized market of tissue imaging and digital pathology, leveraging advanced 3D cell culture models and AI-driven image analysis techniques. The business model is service-based, generating revenue through contract research services provided to its clients. Visikol's expertise in quantitative analysis and its innovative approach to tissue and cell analysis make it a valuable partner in the drug discovery process.
Keywords: 3D cell culture, tissue imaging, digital pathology, drug discovery, AI analysis, confocal microscopy, high content screening, biomarker analysis, pharmaceutical services, biotech research.